By Elise Reuter | Published October 1, 2026
In a significant push to reshape the landscape of modern medicine, the U.S. Food and Drug Administration (FDA) has unveiled the latest cohort of participants for its "READI-Home Innovation Challenge." The initiative is designed to catalyze the development of cutting-edge home medical devices capable of reducing hospital readmissions and shifting the paradigm of patient care from clinical settings to the home environment.
As healthcare systems grapple with rising costs and the logistical strain of inpatient care, the FDA’s "Home as a Healthcare Hub" initiative—launched in 2024 by Center for Devices and Radiological Health (CDRH) Director Michelle Tarver—seeks to integrate the "lived environment" into the design of medical technology. By fostering innovation that prioritizes patient accessibility, the agency aims to bridge the gap in health equity, ensuring that advanced care is not confined to the walls of a hospital.
Main Facts: The READI-Home Innovation Challenge
The READI-Home Innovation Challenge is more than a developmental program; it is a strategic effort by federal regulators to encourage medical device manufacturers to think beyond the hospital-centric model. The initiative focuses on devices that can monitor, treat, or diagnose patients in their own homes, thereby preventing the cycle of discharge and readmission that often burdens both patients and the healthcare system.
The five selected participants represent a cross-section of the medtech industry, ranging from pediatric monitoring solutions to advanced diagnostics for cancer therapy. Each company has been vetted for its potential to lower the barrier to high-quality care, specifically for patients managing complex, long-term conditions.
Chronology: The Evolution of the Home-Health Hub
The road to the READI-Home challenge began with a recognition of systemic failure. For decades, medical device innovation was largely predicated on hospital use, where clinicians controlled the environment. However, the COVID-19 pandemic accelerated the adoption of telehealth and home-based monitoring, revealing that patients were capable of managing complex health tasks if provided with the right tools.
- 2024: CDRH Director Michelle Tarver launches the "Home as a Healthcare Hub" initiative, a cross-disciplinary effort to reconsider how medical devices are designed for home use. The initiative emphasizes the importance of human factors, usability, and the physical constraints of home living.
- Early 2025: The FDA issues a call for submissions for the READI-Home Innovation Challenge, inviting manufacturers to submit technologies that specifically address readmission rates.
- Mid-2025: A rigorous selection process begins, evaluating submissions based on clinical efficacy, safety profiles, and the ability to reduce the need for acute hospital interventions.
- October 2026: The current cohort of five participants is officially announced, marking a milestone in the integration of regulatory oversight and home-based medical technology.
The Five Innovators: Supporting Data and Clinical Focus
The participants in this year’s challenge offer a glimpse into a future where the home is as equipped as an intensive care unit.
1. Epitel: Advancing Neurological Monitoring
Epitel is introducing a wireless, wearable EEG system designed for post-discharge monitoring. Traditional EEG setups are cumbersome and typically require clinical supervision. Epitel’s solution is intended for patients 6 years and older, particularly those being assessed for seizures, sleep disorders, or delirium. By moving the monitoring process home, clinicians can obtain longitudinal data that a single hospital visit might miss.
2. Prapela: Pediatric Cardiac Support
Prapela has developed a specialized crib mattress that utilizes randomized, gentle vibrations. The device is specifically engineered for infants with single-ventricle heart disease. These infants are at high risk for hypoxemic and bradycardic episodes during the critical periods between surgeries. By stabilizing the infant’s condition at home, the Prapela mattress aims to reduce the frequency and severity of these episodes, providing parents with a safer "bridge" during high-risk recovery phases.
3. BD (Becton, Dickinson and Company): Empowering Self-Collection
As part of the initiative, BD is highlighting its home self-collection blood sampling kit. By enabling adults to collect high-quality capillary blood specimens in the comfort of their homes, the kit reduces the need for patients to travel to clinics or laboratories. This is particularly vital for patients with chronic conditions who require frequent monitoring but face mobility challenges or geographic barriers.
4. Current Health: Monitoring CAR-T Therapy
One of the most ambitious projects in the cohort comes from Current Health. The company has developed AI-enabled software aimed at monitoring cancer patients undergoing CAR-T therapy. A major complication of this treatment is cytokine release syndrome (CRS), an immune reaction that can turn life-threatening. By allowing patients to be monitored remotely with high-fidelity analytics, Current Health offers a safer way to manage complex immunotherapy outside of a hospital bed.
5. Skribe Medical: Heart Function Tracking
Skribe Medical is targeting heart failure management through a wearable patch that estimates left ventricular ejection fraction (LVEF). By enabling patients or caregivers to perform this measurement at home, the device provides actionable data to cardiologists. This allows for earlier intervention when heart function begins to decline, potentially avoiding the emergency readmissions common in chronic heart failure patients.
Official Responses and Regulatory Perspective
The FDA’s pivot toward home-based care is driven by the conviction that healthcare equity is impossible if patients are forced to navigate environments that do not support their medical needs.
"The goal is to move the needle on health equity," said a representative from the FDA during the unveiling. "When we design for the home, we are designing for the reality of the patient’s life, not just the controlled environment of a hospital room. These five innovators are proving that medical-grade technology can and should be accessible in the living room, the bedroom, and the kitchen."
The FDA remains committed to providing regulatory pathways that facilitate, rather than hinder, this innovation. By working closely with these companies, the agency is gathering data on how these devices perform in real-world settings, which will inform future guidance on remote patient monitoring and home-based diagnostics.
Implications: The Future of Healthcare Delivery
The implications of the READI-Home Innovation Challenge extend far beyond the five companies involved. As these technologies mature, they promise to fundamentally alter the patient-provider relationship.
Economic Impact
Hospital readmissions are a massive driver of healthcare costs. By providing clinicians with the tools to manage patients remotely, the healthcare system stands to save billions in unnecessary acute care spending. Furthermore, home-based monitoring allows for a more efficient allocation of hospital resources, reserving beds for those who truly require inpatient intervention.
Health Equity
The "Home as a Healthcare Hub" initiative directly addresses disparities in health outcomes. Patients in rural areas or those with limited transportation options often face delays in care that exacerbate their conditions. By decentralizing care, the FDA is fostering a model where geography is no longer a barrier to receiving top-tier medical monitoring.
Data-Driven Care
The integration of AI—as seen in the solutions from Current Health—marks the beginning of a more proactive medical era. Instead of waiting for a patient to report symptoms, providers can receive real-time alerts based on physiological trends. This shift from reactive to predictive care is perhaps the most significant outcome of the initiative.
The Challenges Ahead
Despite the promise, the transition to home-based care is not without hurdles. Issues regarding data privacy, cybersecurity, and the digital divide remain at the forefront. Ensuring that all patients, regardless of socioeconomic status, have the internet connectivity and technological literacy required to operate these devices will be the next major challenge for the FDA and its partners.
Furthermore, physicians must be trained to integrate these massive streams of remote data into their clinical workflows. Without proper systems for data triage, clinicians risk being overwhelmed by information, which could inadvertently lead to diagnostic delays.
Conclusion
The READI-Home Innovation Challenge is a clear signal from the FDA: the future of healthcare is decentralized. By supporting innovators like Epitel, Prapela, BD, Current Health, and Skribe Medical, the agency is not just clearing devices for market—it is helping to build an infrastructure that recognizes the home as a legitimate and critical extension of the healthcare system. As these technologies move toward wider adoption, the hope is that the hospital will eventually become a place for acute intervention, while the home becomes the primary site for recovery, management, and long-term health.
